Filing: the FTC is investigating Amazon's $3.9B One Medical acquisition, which could delay its close; significant US antitrust probes take an average ~11 months
The FTC is investigating https://amazon.com/ Inc.'s $3.9 billion deal to buy1Life Healthcare Inc., which operates One Medical primary care clinics in 25 U.S. markets. https://www.wsj.com/...
Context & Ripple Effects
This filing lands mid-escalation between Amazon and the FTC: days earlier, Amazon accused the agency of harassing Jeff Bezos and Andy Jassy over the Prime membership probe, and by late September the FTC confirmed the executives cannot avoid testifying. The One Medical review extends that friction into M&A, putting a $3.9B bet on brick-and-mortar primary care under antitrust scrutiny.
The arc resolves without a block: in February 2023 the FTC declined to challenge the acquisition and Amazon closed it, but only after roughly five extra months of review — and the agency kept pressing, with sources later describing an FTC pipeline spanning a possible iRobot challenge, a retail antitrust case, and dark-pattern work.
First-order effects
- Amazon's integration of One Medical's clinics across 25 U.S. markets goes on hold while the review runs, against an ~11-month average for significant U.S. antitrust probes.
- 1Life Healthcare shareholders face a longer window between signing and closing, with deal terms exposed to market movement during the delay.
Second-order effects
- The FTC is running this probe alongside the Prime investigation and a possible iRobot challenge, stretching agency resources across multiple Amazon fronts and signaling that every large Amazon deal now gets deep review by default.
- A cleared-but-delayed outcome sets a template rivals can plan around: budget for extended second requests and closing-date slippage rather than outright rejection.
Third-order effects
- If the pattern holds, prolonged review becomes a de facto tax on big-tech acquisitions — deals still close, but the added months raise deal costs and may chill smaller targets from selling to platform giants.
- Healthcare becomes a standing scrutiny zone for tech acquirers, with clinic networks and patient-data assets drawing the same treatment as classic horizontal mergers.
The trend: U.S. antitrust review of major tech acquisitions is shifting from rubber stamp to default deep probe, where delay itself — not just blocking — becomes the regulator's lever.